We use cookies to ensure our website works properly and to personalise your experience. Cookies policy
Assistant Professor, Shree Krishna College of Pharmacy,Sitapur.
Atopic dermatitis (AD) is a chronic relapsing inflammatory skin disorder characterized by severe pruritus, epidermal barrier dysfunction, immune dysregulation, and recurrent inflammatory episodes. The increasing prevalence of AD worldwide has prompted the exploration of safer and more effective therapeutic strategies beyond conventional corticosteroids and immunosuppressive agents. Curcumin, a bioactive polyphenolic constituent isolated from Curcuma longa, possesses remarkable anti-inflammatory, antioxidant, antimicrobial, immunomodulatory, and wound-healing properties. Despite its therapeutic promise, poor aqueous solubility, limited skin permeation, rapid degradation, and low bioavailability restrict its clinical application. Recent advances in topical drug delivery systems, particularly emulgels, nanoemulgels, liposomes, nanostructured lipid carriers, transfersomes, and polymeric nanoparticles, have significantly improved the topical delivery and therapeutic performance of curcumin. [7]This review comprehensively discusses the pathophysiology of atopic dermatitis, pharmacological mechanisms of curcumin, formulation strategies of curcumin-loaded emulgel and nanoemulgel systems, characterization approaches, preclinical and clinical evidence, recent technological advancements, regulatory challenges, and future perspectives. Special emphasis is placed on studies published between 2021 and 2026 concerning nano-enabled topical delivery systems for inflammatory skin disorders. Emerging evidence suggests that curcumin-loaded emulgel systems provide enhanced skin penetration, sustained drug release, improved stability, reduced inflammatory cytokine expression, and superior patient compliance compared with conventional topical formulations. These findings position curcumin-based topical nanotherapeutics as promising alternatives for the management of atopic dermatitis. [7]
Atopic dermatitis (AD), commonly referred to as eczema, is a chronic inflammatory skin disease affecting approximately 15–20% of children and 3–10% of adults globally. The disease is characterized by erythema, xerosis, edema, excoriation, skin thickening, and intense itching that significantly impacts patient quality of life. [32-35]
Current therapeutic approaches involve:
However, long-term therapy frequently leads to adverse effects including skin atrophy, irritation,burning sensation, and immunosuppression.
Natural phytochemicals have attracted considerable interest as safer therapeutic alternatives. Among them, curcumin has emerged as a promising candidate due to its broad-spectrum pharmacological activities and favorable safety profile. [1,2]
Table.1 Current Therapeutic Approaches for Atopic Dermatitis
|
Therapeutic Approach |
Mechanism of Action |
Examples |
|
Topical Corticosteroids [4,9] |
Reduce inflammation, itching, and immune responses in the skin |
Hydrocortisone, Betamethasone, Clobetasol Propionate, Mometasone Furoate |
|
Calcineurin Inhibitors [4,9] |
Inhibit T-cell activation and inflammatory cytokine release |
Tacrolimus Ointment, Pimecrolimus Cream |
|
Janus Kinase (JAK) Inhibitors [4,9] |
Block JAK signaling pathways involved in inflammation |
Ruxolitinib Cream, Upadacitinib, Abrocitinib, Baricitinib |
|
Systemic Immunomodulators [4,9] |
Suppress overactive immune responses in moderate-to-severe disease |
Cyclosporine, Methotrexate, Azathioprine, Mycophenolate Mofetil |
|
Biological Agents (Biologics) [4,9] |
Target specific cytokines involved in atopic dermatitis pathogenesis [4,9,10] |
Dupilumab, Tralokinumab, Lebrikizumab |
2. Global Burden of Atopic Dermatitis [4,9]
Atopic dermatitis is recognized as one of the most common chronic inflammatory skin disorders worldwide. The prevalence has increased dramatically over the last three decades, particularly in industrialized nations. [32-34]
Major factors contributing to disease progression include:
The chronic and recurrent nature of AD often results in psychological distress, sleep disturbances, anxiety, depression, and substantial healthcare expenditures. [4,9,10]
Table 2 Major Factors Contributing to Atopic Dermatitis Disease Progression
|
Contributing Factor |
Role in Disease Progression |
Examples |
|
Genetic Predisposition |
Inherited genetic factors increase susceptibility to atopic dermatitis and other allergic diseases [4,9] |
Family history of atopic dermatitis, asthma, or allergic rhinitis [4,9] |
|
Filaggrin Gene Mutations |
Defective filaggrin protein impairs skin barrier function, leading to increased water loss and allergen penetration |
FLG loss-of-function mutations (e.g., R501X, 2282del4) |
|
Environmental Pollutants |
Pollutants damage the skin barrier and trigger inflammation |
Tobacco smoke, vehicle exhaust, particulate matter (PM2.5), industrial pollutants |
|
Microbial Dysbiosis |
Imbalance of skin microbiota promotes inflammation and skin infections |
Overgrowth of Staphylococcus aureus, reduced microbial diversity |
|
Allergens |
Allergens penetrate the damaged skin barrier and activate immune responses. |
House dust mites, pollen, pet dander, molds, food allergens (milk, eggs, peanuts) |
|
Oxidative Stress |
Excessive production of reactive oxygen species (ROS) damages skin cells and enhances inflammation. |
UV radiation, air pollution, ROS-induced lipid peroxidation |
|
Immune Dysregulation |
Abnormal activation of immune pathways leads to chronic inflammation and itching |
Increased Th2 cytokines (IL-4, IL-5, IL-13), elevated IgE levels |
3. Pathophysiology of Atopic Dermatitis [4,9]
Atopic dermatitis (AD) is a chronic inflammatory skin disorder resulting from a complex interaction of epidermal barrier dysfunction, immune dysregulation, genetic susceptibility, oxidative stress, and environmental factors. These mechanisms collectively contribute to skin inflammation, pruritus, and recurrent disease exacerbations. [32-35]
3.1 Skin Barrier Dysfunction
The hallmark of AD is impairment of the epidermal barrier. [4,9,10]
Consequences:
3.2 Immune Dysregulation
AD is primarily characterized by an exaggerated Type 2 helper T-cell (Th2)-mediated immune response. [4,9,10]
Key cytokines involved include:
These cytokines lead to:
As the disease progresses, additional immune pathways become involved, including:
These immune abnormalities further amplify inflammation and contribute to chronic disease progression.
3.3 Oxidative Stress
Oxidative stress plays a significant role in the pathogenesis of AD through excessive production of reactive oxygen species (ROS). [16-18,35]
Oxidative stress contributes to:
Consequences include:
3.4 Itch–Scratch Cycle
Pruritus is a defining symptom of AD and is largely mediated by cytokines such as IL-31. [4,9,10]
3.5 Microbial Dysbiosis
Patients with AD frequently exhibit altered skin microbiota, particularly colonization by Staphylococcus aureus. [4,9,10]
Figure 1. Pathophysiology of Atopic Dermatitis
4. Curcumin: Chemistry and Pharmacological Profile [1,2]
Curcumin is a naturally occurring polyphenol extracted from turmeric (Curcuma longa). [11,13-15,20-24]
Chemical Characteristics
Biological Activities
Recent dermatological investigations indicate substantial therapeutic potential against:
Figure 2. Chemical Structure of Curcumin
5. Molecular Mechanisms of Curcumin in Atopic Dermatitis [1,2]
Curcumin acts through multiple signaling pathways. [1,2]
5.1 NF-κB Inhibition
Curcumin suppresses NF-κB activation, thereby reducing: [1-3]
5.2 COX-2 Suppression
Curcumin inhibits cyclooxygenase-mediated prostaglandin synthesis. [1,2]
5.3 Antioxidant Action
Curcumin scavenges: [1,2]
and activates Nrf2-mediated antioxidant defense pathways.
5.4 Modulation of Skin Barrier Function
Experimental studies suggest curcumin improves: [1,2]
Figure 3. Molecular Mechanisms of Curcumin in AD
6. Limitations of Curcumin Therapy [1,2]
Despite its therapeutic promise, curcumin suffers from: [11,12,20,23-25]
These challenges have stimulated extensive research into advanced drug delivery systems.
7. Topical Drug Delivery Systems for Curcumin [1,2]
7.1 Conventional Systems
Limitations
7.2 Advanced Delivery Systems
Nanoemulsions [11,25]
Provide:
Liposomes [5,6,10]
Facilitate:
Transfersomes [5,6,10]
Enhance transdermal transport through deformable vesicles. [4,9]
Polymeric Nanoparticles [5,6,25]
Improve:
8. Emulgel Technology [7,9]
8.1 Concept of Emulgel
Emulgels combine: [7,9]
to create a dual-controlled drug delivery platform.
8.2 Advantages
9. Nanoemulgel Systems [7]
Nanoemulgels represent the next generation of emulgel technology. [7,11]
Advantages
Nanoemulgels have demonstrated superior performance compared with conventional emulgels in inflammatory skin disorders. [7]
10. Formulation Components Used in Curcumin Emulgels [1,2]
Oil Phase
Surfactants
Gelling Agents
Permeation Enhancers
11. Characterization Techniques
Preformulation Studies
Nanoformulation Characterization [5,6,10]
Evaluation Parameters
12. Recent Advances (2021–2026)
Recent studies have reported: [6,11,12,14,15]
These systems demonstrated enhanced anti-inflammatory effects and improved skin penetration compared with conventional formulations. [4,9]
13. Clinical Evidence
Several clinical investigations have demonstrated beneficial effects of curcumin-containing topical formulations in inflammatory skin disorders. [13-15,20-24]
Observed outcomes include:
However, large randomized controlled trials remain limited.
14. Safety and Toxicological Considerations
Curcumin exhibits excellent safety. [13,20,21,24]
Reported observations include:
Nevertheless, formulation-specific safety evaluations remain essential.
15. Challenges and Regulatory Considerations
Major barriers to commercialization include: [11,19,25-29]
16. Future Perspectives
Future research should focus on: [6,11,16-19,30,31]
REFERENCES
Vinod Kumar, Sadhna Rajvanshi, Curcumin-Based Emulgel and Nanoemulgel Systems for Atopic Dermatitis: Recent Advances, Therapeutic Potential, and Future Perspectives, Int. J. of Pharm. Sci., 2026, Vol 4, Issue 7, 6097-6107, https://doi.org/10.5281/zenodo.21721765
10.5281/zenodo.21721765